Caribou Biosciences
Most recent annual filing: 2026-03-05
- vispa-cel Ph1 readout2026vispa-cel Ph1 readout, 2026, major
- CB-011 interim2026CB-011 interim, 2026, major
- Caribou corporate financing2026Caribou corporate financing, 2026, notable
- Corporate/Financing or Partnership financing2H 2026Corporate/Financing or Partnership financing, 2H 2026, notable
- ANTLER-3 guidance updateend of 2027ANTLER-3 guidance update, end of 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
CB-011
Technology platforms
chRDNA
CRISPR hybrid RNA-DNA (chRDNA) genome-editing technology using hybrid guides containing both RNA and DNA for editing genomic DNA; enables high-specificity multiplex genome editing for ex vivo allogeneic CAR-T cell therapies; focus areas include oncology and autoimmune diseases
Targets: CD19, BCMA
Discontinued (2)
- vispacabtagene regedleucel — Lupus · discontinued GALLOP phase 1 trial prior to dosing the first patient as part of strategic pipeline prioritization
- CB-012 — Relapsed/Refractory Acute Myeloid Leukemia · discontinued AMpLify phase 1 clinical trial as additional data would be needed to advance this program; license agreement with MSKCC terminated
Biotech Distilled coverage (4)
- 2026-08-14 UPDATE: Caribou Biosciences (CRBU) - The ATM Stopped Being a Token 🔒 Paid
- 2026-06-11 UPDATE: Caribou Biosciences (CRBU) - The Durability Box Gets Checked
- 2026-05-08 UPDATE: Caribou Biosciences (CRBU) - The FDA Said Yes, The Bank Account Said “About That...” 🔒 Paid
- 2026-04-17 Caribou Biosciences (CRBU) - Scientific Deep Dive for Vispa-cel and CB-011 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.